Recombinant osteochondrogenic stem cells and preparation method and application thereof
By introducing the coding gene of desmosomal cordin 2 into the osteochondral stem cells, recombinant osteochondral stem cells were prepared, and the problem of limited bone regeneration effect in the prior art was solved, and bone fractures, bone defects, bone degenerative changes and bone bones were achieved. Effective treatment of diseases such as looseness.
Patent Information
- Application Number
- CN202410327922.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-21
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-03-21
AI Technical Summary
The prior art has limited effectiveness in promoting bone regeneration, especially in diseases such as osteoporosis, bone defects, fractures and bone degenerative changes, where effective bone regeneration promoters are lacking.
Recombinant osteochondral stem cells were prepared by introducing the encoding gene of desmosomal cordin 2 into the ex vivo osteochondral stem cells to treat insufficient bone regeneration.
Recombinant osteochondral stem cells can effectively promote bone regeneration and are used to treat diseases such as fractures, bone defects, bone degenerative changes and osteoporosis, significantly improving bone regeneration capabilities.
Smart Images

Figure CN118421565B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to recombinant osteochondral stem cells in the field of genetic engineering and a preparation method and application thereof. Background Art
[0002] Bone regeneration refers to the generation of new bone tissue in physiological and pathological states, which participates in the development of the skeletal system, maintains the homeostasis of the skeletal system, fights against skeletal system aging, and promotes the repair of skeletal system damage. With the aging of the population, insufficient bone regeneration such as osteoporosis, bone defects, fractures, and bone degenerative changes has threatened human health and affected the quality of life of patients. Therefore, the need to find effective bone regeneration promoters has become increasingly urgent.
[0003] At present, clinical methods for promoting bone repair have problems such as insufficient sources of autologous bone transplants, and immune rejection and infection risks in allogeneic bone transplants. Stem cell transplantation therapy has good application prospects for tissue regeneration and repair, and has been widely studied and applied in diseases related to insufficient bone regeneration, showing excellent regeneration and repair capabilities. However, many stem cell therapies have not yet achieved satisfactory clinical treatment results. Gene-enhanced stem cell therapy is a cutting-edge biomedical technology that combines the principles of gene editing and stem cell therapy. It uses high-throughput sequencing technology to screen key functional genes of stem cells. Gene editing technology enhances the key genes of stem cells to give them specific functions or characteristics. These enhanced stem cells can be used to repair damaged tissues and organs, and more effectively promote tissue regeneration and repair.
[0004] Therefore, given the current limited efficacy of stem cells, there is an urgent need to develop new functionally enhanced stem cell products by combining high-throughput sequencing technology with gene editing technology to effectively promote bone regeneration. Summary of the invention
[0005] The technical problem to be solved by the present invention is how to provide a cell product capable of treating insufficient bone regeneration. The technical problem to be solved is not limited to the technical subject described, and those skilled in the art can clearly understand other technical subjects not mentioned herein through the following description.
[0006] In order to solve the above technical problems, the present invention provides the following technical solutions:
[0007] The present invention provides recombinant osteochondral stem cells, which are prepared according to a method comprising the following steps: introducing a gene encoding desmoglein 2 into an isolated osteochondral stem cell to obtain the recombinant osteochondral stem cell.
[0008] The recombinant osteochondrogenic stem cells express desmoglein 2.
[0009] The desmoglein 2 is any of the following proteins:
[0010] A1) a protein whose amino acid sequence is SEQ ID No. 1;
[0011] A2) a protein having more than 80% identity with the protein shown in A1) and having the same function as the protein shown in A1) obtained by substitution and / or deletion and / or addition of amino acid residues of the amino acid sequence shown in SEQ ID No.1;
[0012] A3) A fusion protein having the same function is obtained by connecting a tag to the N-terminus and / or C-terminus of A1) or A2).
[0013] The tag protein includes but is not limited to: GST (glutathione sulfhydryltransferase) tag protein, His6 tag protein (His-tag), MBP (maltose binding protein) tag protein, Flag tag protein, SUMO tag protein, HA tag protein, Myc tag protein, eGFP (enhanced green fluorescent protein), eCFP (enhanced cyan fluorescent protein), eYFP (enhanced yellow-green fluorescent protein), mCherry (monomeric red fluorescent protein) or AviTag tag protein.
[0014] Herein, identity refers to the identity of an amino acid sequence or a nucleotide sequence. The identity of an amino acid sequence can be determined using a homology search site on the Internet, such as the BLAST webpage on the NCBI homepage website. For example, in Advanced BLAST2.1, by using blastp as a program, setting the Expect value to 10, setting all Filters to OFF, using BLOSUM62 as a Matrix, setting Gap existence cost, Per residue gap cost and Lambda ratio to 11, 1 and 0.85 (default values) respectively and searching to calculate the identity of an amino acid sequence, the value (%) of identity can then be obtained.
[0015] Herein, the 80% or greater identity may be at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity.
[0016] In the above-mentioned recombinant osteochondral stem cells, the osteochondral stem cells are derived from humans.
[0017] The recombinant osteochondrogenic stem cells provided by the present invention can be used to treat diseases of insufficient bone regeneration.
[0018] The above-mentioned diseases of insufficient bone regeneration include osteogenesis imperfecta, fractures and bone defect diseases.
[0019] By detecting the expression level of the DSG2 encoding gene and / or the expression product of the DSG2 encoding gene, the progression of the disease related to abnormal bone regeneration can be diagnosed, detected, monitored or predicted; experiments have shown that DSG2 is correlated with bone regeneration ability, and the expression of DSG2 increases with the increase of the degree of osteosclerosis, and the high expression of DSG2 can indicate pathological hyperactivity of bone regeneration. Therefore, the DSG2 encoding gene and its expression product can be used as a biomarker for diagnosis and / or prognosis of abnormal bone regeneration diseases.
[0020] The present invention provides a method for preparing recombinant osteochondral stem cells, which comprises the following steps: introducing a gene encoding desmoglein 2 into isolated osteochondral stem cells to obtain the recombinant osteochondral stem cells.
[0021] The desmoglein 2 coding gene is a cDNA molecule or a DNA molecule whose coding sequence is SEQ ID No.2.
[0022] In the above method, the recombinant osteochondrogenic stem cells express desmoglein 2.
[0023] In the above method, the osteochondral tissue is derived from human. The osteochondral tissue includes subchondral bone and hyaline cartilage.
[0024] The present invention also provides a drug for promoting bone regeneration, which is composed of pharmaceutical excipients and the aforementioned recombinant osteochondrocyte stem cells.
[0025] The dosage form of the drug is injection.
[0026] The pharmaceutical excipients include physiologically or pharmaceutically acceptable carriers or excipients. Herein, "physiologically or pharmaceutically acceptable carriers" refer to those carriers and diluents that have no obvious irritation to the organism and do not damage the biological activity and performance of the reagents in the taken pharmaceutical composition. The carrier materials here include but are not limited to water-soluble carrier materials (such as polyethylene glycol, polyvinyl pyrrolidone, organic acids, etc.), poorly soluble carrier materials (such as ethyl cellulose, cholesterol stearate, etc.). Among them, water-soluble carrier materials are preferred. In order to prepare unit dosage forms into injection preparations, such as solutions, emulsions, freeze-dried powder injections and suspensions, all diluents commonly used in the art can be used, for example, water, ethanol, polyethylene glycol, 1,3-propylene glycol, ethoxylated isostearyl alcohol, polyoxygenated isostearyl alcohol, polyoxyethylene sorbitol fatty acid esters, etc. In addition, in order to prepare isotonic injections, an appropriate amount of sodium chloride, glucose or glycerol can be added to the injection preparation. In addition, conventional cosolvents, buffers, pH regulators, etc. can also be added.
[0027] The present invention also provides the use of recombinant osteochondral stem cells in the preparation of a drug for promoting bone regeneration, wherein the recombinant osteochondral stem cells are the aforementioned recombinant osteochondral stem cells.
[0028] The present invention also provides the use of protein in preparing a drug for promoting bone regeneration, wherein the protein is desmoglein 2.
[0029] The insufficient bone regeneration includes, but is not limited to, fractures, bone defects, bone degenerative changes and osteoporosis caused by various reasons.
[0030] The present invention also provides the use of a biomaterial in the preparation of a drug for promoting bone regeneration, wherein the biomaterial is any one of the following:
[0031] B1), a nucleic acid molecule encoding desmoglein 2;
[0032] B2), an expression cassette containing the nucleic acid molecule described in B1);
[0033] B3), a recombinant vector containing the nucleic acid molecule described in B1), or a recombinant vector containing the expression cassette described in B2);
[0034] B4), a recombinant microorganism containing the nucleic acid molecule described in B1), or a recombinant microorganism containing the expression cassette described in B2), or a recombinant microorganism containing the recombinant vector described in B3);
[0035] B5), a transgenic animal cell line containing the nucleic acid molecule described in B1), or a transgenic animal cell line containing the expression cassette described in B2);
[0036] B6), transgenic animal tissue containing the nucleic acid molecule described in B1), or transgenic animal tissue containing the expression cassette described in B2);
[0037] B7), transgenic animal organs containing the nucleic acid molecule described in B1), or transgenic animal organs containing the expression cassette described in B2).
[0038] The desmoglein 2 coding gene is a cDNA molecule or a DNA molecule whose coding sequence is SEQ ID No.2.
[0039] Among the above substances, the expression cassette containing nucleic acid molecules described in B2) refers to DNA capable of expressing the above-mentioned proteins in host cells. The expression cassette may also include single-stranded or double-stranded nucleic acid molecules containing all regulatory sequences necessary for expressing the nucleic acid molecules of any of the above-mentioned proteins. The regulatory sequence can guide the coding sequence to express any of the above-mentioned proteins in a suitable host cell under compatible conditions. The regulatory sequence includes, but is not limited to, a leader sequence, a polyadenylation sequence, a propeptide sequence, a promoter, a signal sequence and a transcription terminator. At a minimum, the regulatory sequence should include a promoter and termination signals for transcription and translation. In order to introduce specific restriction enzyme sites into the vector so as to connect the regulatory sequence to the coding region of the nucleic acid sequence encoding the protein, a regulatory sequence with a linker may be provided. The regulatory sequence may be a suitable promoter sequence, i.e., a nucleic acid sequence that can be recognized by the host cell expressing the nucleic acid sequence. The promoter sequence contains a transcriptional regulatory sequence that mediates protein expression. The promoter may be any nucleic acid sequence that has transcriptional activity in the selected host cell, including mutant, truncated and hybrid promoters, and may be obtained from a gene encoding an extracellular or intracellular protein that is homologous or heterologous to the host cell. The regulatory sequence may also be a suitable transcription termination sequence, i.e., a sequence that can be recognized by the host cell to terminate transcription. The termination sequence may be operably linked to the 3' end of the nucleic acid sequence encoding the protein. Any terminator that can function in the selected host cell may be used in the present invention. The regulatory sequence may also be a suitable leader sequence, i.e., an untranslated region of mRNA that is important for translation of the host cell. The leader sequence may be operably linked to the 5' end of the nucleic acid sequence encoding the protein. Any leader sequence that can function in the selected host cell may be used in the present invention. The regulatory sequence may also be a signal peptide coding region that encodes an amino acid sequence attached to the amino terminus of the protein that can guide the encoded protein into the cell secretory pathway. Signal peptide coding regions that can guide the expressed protein into the secretory pathway of the host cell used may be used in the present invention. It may also be desirable to add regulatory sequences that can regulate protein expression according to the growth of the host cell. Examples of regulatory sequences are systems that can respond to chemical or physical stimuli (including in the presence of regulatory compounds) to open or close gene expression. Other examples of regulatory sequences are those that can amplify genes.
[0040] As used herein, "treating" means alleviating, in whole or in part, the symptoms associated with a condition or disorder (eg, a disease), or halting further progression or worsening of these symptoms, or preventing or prophylaxis of the disease or disorder.
[0041] The present invention proves through experiments that DSG2 is correlated with bone regeneration ability, and recombinant osteochondrogenic stem cells prepared by lentiviral vector construction can be used to treat diseases with insufficient bone regeneration, such as fractures, bone defects, bone degenerative changes and osteoporosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1 The UMAP diagram shows the types of osteochondral stem cell populations in mild and severe bone regeneration abnormal hyperactivity tissues detected by single-cell sequencing. Among them, red represents osteochondral stem cell population 1, yellow represents osteochondral stem cell population 2, green represents osteochondral stem cell population 3, cyan represents osteochondral stem cell population 4, blue represents osteochondral stem cell population 5, and pink represents osteochondral stem cell population 6. UMAP_1 represents unified manifold approximation and projection dimension 1, and UMAP_2 represents unified manifold approximation and projection dimension 2.
[0043] Figure 2 The expression of sclerosis-related genes in abnormal bone regeneration tissues. Among them, 1 is mild abnormal bone regeneration tissue, 2 is severe abnormal bone regeneration tissue; the first picture from left to right is POSTN, i.e. periostin, the second picture from left to right is COL1A1, i.e. type I collagen alpha 1 chain, the third picture from left to right is COL3A1, i.e. type III collagen alpha 1 chain, and the fourth picture from left to right is SPP1, i.e. secretory phosphoprotein 1.
[0044] Figure 3 A group of osteochondral stem cells with high expression of DSG2 that specifically increase during abnormal bone regeneration. The left picture shows the results of osteochondral tissue with mild abnormal bone regeneration, and the right picture shows the results of osteochondral tissue with severe abnormal bone regeneration. Purple indicates the transcriptional expression level of DSG2. UMAP_1 in the left picture represents unified manifold approximation and projection dimension 1, and UMAP_2 represents unified manifold approximation and projection dimension 2. UMAP_1 in the right picture represents unified manifold approximation and projection dimension 1, and UMAP_2 represents unified manifold approximation and projection dimension 2.
[0045] Figure 4 The violin plots show the transcriptional expression level of DSG2 in osteochondral tissue with abnormal bone regeneration. 1 is a tissue with mild abnormal bone regeneration, and 2 is a tissue with severe abnormal bone regeneration.
[0046] Figure 5The fluorescence expression of human osteochondral stem cells infected with lentivirus. The left picture is a fluorescence picture of osteochondral stem cells infected with lentivirus containing an empty vector, and the right picture is a fluorescence picture of osteochondral stem cells infected with lentivirus expressing DSG2. The green fluorescence in the left picture indicates osteochondral stem cells infected with lentivirus containing an empty vector plasmid, and the green fluorescence in the right picture indicates osteochondral stem cells infected with lentivirus expressing DSG2.
[0047] Figure 6 These are the Western blotting results of human osteochondrogenic stem cells stably transfected with an empty plasmid and osteochondrogenic stem cells modified by overexpression of the DSG2 gene. The first row from top to bottom is DSG2 (the first lane is an empty vector, and the second lane is overexpressed DSG2), and the second row from top to bottom is GAPDH (the first lane is an empty vector, and the second lane is overexpressed DSG2).
[0048] Figure 7 for Figure 6 Relative quantitative analysis results of Western blotting electrophoresis bands. p <0.001.
[0049] Figure 8 The results of alkaline phosphatase (ALP) staining of human osteochondrogenic stem cells stably transfected with an empty vector and osteochondrogenic stem cells overexpressing the DSG2 gene after osteogenic differentiation. The left picture shows an empty vector, and the right picture shows overexpression of DSG2. The red color in the left picture indicates the ALP expression of human osteochondrogenic stem cells stably transfected with an empty vector after osteogenic differentiation, and the red color in the right picture indicates the ALP expression of human osteochondrogenic stem cells overexpressing the DSG2 gene after osteogenic differentiation.
[0050] Fig. 9 for Figure 8 The relative quantitative analysis results of ALP expression in p <0.01.
[0051] Fig.10Results of immunofluorescence staining of OCN and RUNX2, key genes required for bone regeneration, expressed in bone organoids generated by human osteochondrogenic stem cells stably transfected with empty plasmids and osteochondrogenic stem cells overexpressing the DSG2 gene. Figure 1 in the first column from left to right shows the fluorescence expression of OCN and RUNX2 in bone organoids generated by human osteochondrogenic stem cells stably transfected with empty plasmids, where red fluorescence indicates positive expression of OCN, and green fluorescence indicates positive expression of RUNX2. Figure 2 is a partial enlarged view of the boxed part in Figure 1, where red fluorescence indicates positive expression of OCN, and green fluorescence indicates positive expression of RUNX2; Figure 1 in the second column from left to right shows the immunofluorescence expression of OCN and RUNX2 in bone organoids generated by human osteochondrogenic stem cells overexpressing the DSG2 gene, where red fluorescence indicates positive expression of OCN, and green fluorescence indicates positive expression of RUNX2. Figure 2 is a partial enlarged view of the boxed part in Figure 1, where red fluorescence indicates positive expression of OCN, and green fluorescence indicates positive expression of RUNX2.
[0052] Fig.11 for Fig.10 Relative quantitative analysis results of the number of cells co-expressing OCN and RUNX2, "*" indicates p <0.05. DETAILED DESCRIPTION
[0053] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.
[0054] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.
[0055] Example 1: Bioinformatics level DSG2 expression is increased in osteochondral tissue of patients with abnormal hyperbone regeneration
[0056] 1. Acquisition of tissue with abnormal bone regeneration
[0057] Discarded mild and severe osteosclerotic tissues were collected from the hospital (the patients had signed informed consent).
[0058] 2. Preparation of Single Cell Suspension
[0059] Wash the tissue three times with PBS buffer (containing 0.5% BSA), and chop the tissue as finely as possible with scissors; add 1.5 mL RPMI 1640 (Collagenase Ⅱ, final concentration 2 mg / mL) to a 2 mL centrifuge tube, and place the sample in a 37°C environment for digestion for 10 h, during which the centrifuge tube can be rotated on a rotator (12 rpm); place a 70 μm filter on a 15 mL centrifuge tube, filter and collect the sample, and wash the 70 μm filter and 2 mL centrifuge tube with RPMI 1640 culture medium, respectively, to a final volume of about 10 mL; centrifuge at 4°C 300 g for 5 min, completely aspirate the supernatant, resuspend the cells with 400 μL PBS, and perform AO / PI staining for quality inspection. Depending on the digestion effect, perform red blood cell lysis, removal of dead cells, and removal of debris.
[0060] 3.10× Genomics library construction and sequencing
[0061] The library was constructed using the Single Cell 3' Reagent Kit*s v2 kit.
[0062] 4. Data Analysis
[0063] CellRanger (V 6.1.2) was used to align the raw fastq data; the human transcriptome sequence used was GRCh38-3.0.0 (https: / / genome.ucsc.edu / ); and the gene expression matrix was finally obtained;
[0064] Seurat software (version: 4.1.1) was used to perform quality control on the original expression matrix, and cells were removed if they met any of the following conditions: filtering out genes with less than 3 cells and cells with less than 200 genes; the number of genes expressed was less than 500 and greater than 7500; the proportion of mitochondrial gene expression was higher than 15%.
[0065] The original data were standardized (LogNormalize, scaling factor 10000). The FindVariableFeatures function was used to find 2000 highly variable features (HVGs). Unsupervised dimensionality reduction was performed on HVGs using PCA (Principal Component Analysis) (30 principal components were selected). The FindClusters function was used to perform clustering based on the Louvain algorithm. The data of mild and severe osteosclerosis were integrated and analyzed.
[0066] After the subgroups were divided, the identified osteochondral tissue stem cells were further classified. The FindAllMarkers function was used to identify the differentially expressed genes (DEGs) of each subgroup, and 6 new subgroups were divided. The DimPlot function was used for dimensionality reduction visualization ( Figure 1 ), use the VlnPlot function to display the expression level of genes in each sample ( Figure 2 ,4), use the FeaturePlot function to display the expression range of genes in the UMAP map ( Figure 3 ).
[0067] 5. Results
[0068] Figure 1 This is a combined analysis of the UMAP map of osteochondral stem cell populations in tissues with mild and severe hyperosteogenetic abnormalities, and a total of 6 cell types were identified. Figure 2 The expression of genes related to sclerosis in mild and severe hyperosteogenetic tissues. The higher the position of the black dot (in the image), the higher the gene expression level. The results show that the degree of sclerosis of osteochondral stem cells in osteochondral tissue with severe hyperosteogenetic tissue is higher than that in osteochondral tissue with mild hyperosteogenetic tissue. Figure 3 It is a group of osteochondral stem cells expressing DSG2 that is specifically increased in osteochondral tissue with severe hyperosteogeny of bone regeneration, indicating that the osteochondral stem cell population in osteochondral tissue with severe hyperosteogeny of bone regeneration activity expresses higher levels of DSG2. Figure 4 The DSG2 transcriptional expression level in osteochondral tissue with abnormal bone regeneration is shown in Table 1. It can be seen that the DSG2 transcriptional expression level in cells derived from tissues with severe abnormal bone regeneration is higher than that in tissues with mild abnormal bone regeneration. The results show that at the bioinformatics level, the expression of DSG2 is positively correlated with the degree of bone sclerosis.
[0069] Example 2: High expression of DSG2 enhances the bone regeneration ability of osteochondral stem cells
[0070] 1. Construction of DSG2 recombinant overexpression vector
[0071] The recombinant overexpression plasmid GV492-DSG2 carrying the DSG2 sequence is a DSG2 gene expression vector obtained by replacing the nucleotide sequence between the AgeI and Bam HI restriction recognition sites of the tool vector plasmid GV492 (GFP & Puro) (Gene Gene Corporation, recorded in the non-patent document "Qingtuan Meng, LeWang, Rujia Dai, Jiawen Wang, Zongyao Ren, Sihan Liu, Yan Xia, Yi Jiang, Fangyuan Duan, Kangli Wang, Chunyu Liu, Chao Chen. Integrative analyses prioritize GNL3 as a risk gene for bipolar disorder. Mol Psychiatry. 2020Nov;25(11):2672-2684. doi: 10.1038 / s41380-020-00866-5." in the document as "GV492") by the DNA molecule shown in SEQ ID No.2 and keeping the other nucleotide sequences of GV492 (GFP & Puro) unchanged. The recombinant overexpression plasmid GV492-DSG2 expresses DSG2 protein.
[0072] 2. Lentivirus Preparation
[0073] Preparation of lentivirus overexpressing DSG2: The recombinant overexpression plasmid GV492-DSG2, viral packaging helper plasmid Helper 1.0 (Gene Gene) and viral packaging helper plasmid Helper 2.0 (Gene Gene) were co-transfected into 293T cells. The cell supernatant was harvested 48-72 hours after transfection and concentrated and purified to obtain high-titer lentivirus overexpressing DSG2.
[0074] Preparation of lentivirus containing empty plasmid (empty vector): Replace the recombinant overexpression plasmid GV492-DSG2 with the GV492 (GFP & Puro) vector empty plasmid. The rest of the operation is the same as the operation steps for preparing lentivirus overexpressing DSG2 to obtain a lentivirus containing an empty plasmid.
[0075] 3. Transfect cells with lentivirus
[0076] Complete medium: liquid medium obtained by adding FBS, penicillin and streptomycin to α-MEM medium (Gibco, catalog number C12571500BT), wherein the volume percentage of FBS is 10%, the content of penicillin is 100 units / ml, and the content of streptomycin is 100 ng / ml.
[0077] 1) Human osteochondrogenic stem cells were cultured at 4 × 10 4 The density of cells / well was inoculated on a six-well plate, and the cell growth density was observed under a microscope. When the cell density reached about 30%, the virus was infected. According to the MOI of infected cells and the virus titer, the corresponding volume of overexpressed DSG2 lentivirus and lentivirus containing empty plasmid were added respectively, and the MOI of recipient human osteochondrogenic stem cell infection was 50. Calculation formula: virus volume = (MOI × number of cells) / virus titer. Preparation of infection system: Add 20 μL 25×HitransG A transfection solution (Jikai Gene Company) and the corresponding volume of virus solution to 1 mL of complete culture medium. Culture at 37℃ for 72 hours, replace with complete culture medium, and continue to culture at 37℃ and 5% CO2.
[0078] 2) Three days after transfection, the expression of green fluorescent protein in cells was observed under a fluorescence microscope. The cells infected with the DSG2-overexpressing lentivirus and the lentivirus containing an empty plasmid were screened for resistance by adding puromycin at 1 μg / mL. Uninfected recipient human osteochondrocyte stem cells were used as controls. The screening ended when the cells in the control group died completely.
[0079] 3) Continue to culture the virus-infected recipient human osteochondral stem cells, perform routine subculture on the recipient human osteochondral stem cells, and finally subculture to 75 cm 2 Cell culture flask.
[0080] 4) Extract the protein of the cells obtained in step 3) and detect the expression of DSG2 by Western blotting. The primary antibody, secondary antibody and dilution ratio used are as follows: DSG2 antibody (1:1000, abcam, ab96761). The internal reference protein antibody uses GAPDH antibody (1:3000, Servicebio, GB11002), and the secondary antibody is HRP-labeled goat anti-rabbit IgG (1:3000, Servicebio, GB23303).
[0081] The results of fluorescence microscopy observations were as follows Figure 5 As shown, the left figure is a fluorescence image of osteochondral stem cells infected with a lentivirus containing an empty plasmid, and the right figure is a fluorescence image of osteochondral stem cells infected with a lentivirus expressing DSG2. The results show that human osteochondral stem cells infected with a lentivirus expressing DSG2 and a lentivirus containing an empty plasmid clearly express green fluorescence.
[0082] Western blotting results Figure 6 and Figure 7 As shown, Figure 6The first lane of the first row from top to bottom is the DSG2 expression level in human osteochondral stem cells infected with a lentivirus containing an empty plasmid, and the second lane is the DSG2 expression level in human osteochondral stem cells infected with a lentivirus expressing DSG2. The first lane of the second row from top to bottom is the GAPDH expression level in human osteochondral stem cells infected with a lentivirus containing an empty plasmid, and the second lane is the GADPH expression level in human osteochondral stem cells infected with a lentivirus expressing DSG2. The results show that the DSG2 expression level in human osteochondral stem cells infected with a lentivirus expressing DSG2 is significantly higher than that in human osteochondral stem cells infected with a lentivirus containing an empty plasmid. It can be seen that the overexpression DSG2 vector was successfully constructed.
[0083] In summary, the human osteochondrocyte stem cells infected with the DSG2-overexpressing lentivirus were named human osteochondrocyte stem cells modified with the DSG2-overexpressing gene. The human osteochondrocyte stem cells infected with the lentivirus containing the empty plasmid were named human osteochondrocyte stem cells stably transfected with the empty plasmid.
[0084] Wherein, the recipient human osteochondral stem cells (also called human osteochondral stem cells) are P3 osteochondral stem cells, which are prepared according to the following method:
[0085] 1. Acquisition of joint platform tissue
[0086] Discarded human knee tibial plateau tissues were collected from the hospital (the patients had signed informed consent).
[0087] 2. Isolation and Culture of Osteochondral Stem Cells
[0088] The following operations were all performed under sterile conditions.
[0089] 1) The lateral (non-stress-bearing side) osteochondral tissue (including subchondral bone and hyaline cartilage) of the collected human knee tibial plateau tissue (the patient has signed the informed consent form) was cut into pieces with a diameter of 1-2 mm using bone scissors.
[0090] 2) Wash the chopped osteochondral tissue in step 1) three times with PBS containing 1% double antibody, add 37℃ preheated digestion solution (0.1% type I collagenase + 0.1% type II collagenase, purchased from Sigma-Aldrich) twice the volume of the osteochondral tissue to obtain an enzymatic reaction system, vortex mix and place in a shaker at 37℃ 80 rpm for digestion for 2 hours to obtain digested osteochondral tissue.
[0091] 3) Centrifuge the osteochondral tissue that has been enzymatically digested in step 2), discard the digestion solution, add 5 mL of PBS containing 1% double antibody to the centrifuge tube for resuspending, centrifuge at 500 rpm for 3 min, discard the supernatant, and take the precipitate to obtain the cleaned osteochondral tissue block.
[0092] 4) Use forceps to transfer the cleaned osteochondral tissue from step 3) to a 25 cm 2 Add about 5 mL of the above complete culture medium to the culture flask, move it to the incubator and culture it for 3 days without moving the culture flask. The cells are the P0 generation human osteochondrocyte stem cells (P0 for short).
[0093] 5) When the P0 human osteochondrogenic stem cells grow to a fusion rate of 80%-90%, remove the culture medium in the culture flask and add 0.25% EDTA-trypsin (Servicebio, catalog number G4004-100ML) for digestion. When the cells become round, add 2 times the volume of the above complete medium to terminate the digestion. After centrifugation, resuspend in 15mL complete medium and inoculate to 75cm 2 The culture flask was placed in a 37°C, 5% carbon dioxide incubator for culture, and the medium was replaced with α-MEM medium containing 10% FBS (a liquid medium obtained by adding FBS to α-MEM medium, wherein the volume content of FBS in the liquid medium is 10%) every 3 days to obtain P1 generation human osteochondrogenic stem cells (abbreviated as P1).
[0094] 6) According to the method shown in step 5), the P1 human osteochondrogenic stem cells were subcultured (the subculture ratio was 1:3) and cultured (the culture medium was α-MEM medium containing 10% FBS, the culture conditions were 37°C, 5% CO2) to the P3 generation, and named as the P3 human osteochondrogenic stem cells (abbreviated as P3).
[0095] IV. Osteogenic differentiation results of human osteochondrogenic stem cells overexpressing DSG2 gene
[0096] 1) Experimental group: Human osteochondrocyte stem cells modified by overexpressing DSG2 gene obtained in the above “3. Lentiviral cell transfection” were cultured at 5×10 3 Cells / well were seeded in a 48-well plate, and 300 μL of α-MEM medium containing 10% FBS was added to each well. On the second day, the medium was replaced with osteogenic induction medium (purchased from cyagen, product number HUXMX-90021), and then replaced every 3 days to observe cell morphological changes. After 10 days of induction, alkaline phosphatase (ALP) staining was performed.
[0097] 2) Control group: Human osteochondrocyte stem cells stably transfected with empty plasmids were used to replace human osteochondrocyte stem cells overexpressing DSG2 gene, and other operations were the same as those of the experimental group.
[0098] The results of ALP staining were Figure 8 and Fig. 9 As shown, Figure 8 The left image in the middle shows an empty vector, and the right image shows overexpression of DSG2. The expression of ALP indicates the early osteogenic differentiation of cells. ALP in cells turns red after being treated with a staining reagent. The experimental group (right side) has more red staining, which is Figure 8 Relative quantitative analysis showed that there were more osteoblastic differentiated cells in the human osteochondrocyte stem cells overexpressing DSG2 in the experimental group, and overexpression of DSG2 gene modification could increase the osteogenic ability of osteochondrocyte stem cells.
[0099] 5. OCN / RUNX2 immunofluorescence staining of subcutaneous transplants of nude mice with human osteochondrogenic stem cells overexpressing DSG2
[0100] 1) Experimental group: Human osteochondrocyte stem cells overexpressing DSG2 gene were digested with trypsin, and the cell concentration was adjusted to 5×10 using an appropriate amount of Matrix gel. 6 Cells / mL. The cells were injected subcutaneously into 8-week-old nude mice (purchased from Vitallife, product number, strain code: 401) with an injection volume of 0.2 mL. The size of the cell clumps was observed daily after injection. After 4 weeks, the cell clumps were sampled, fixed, paraffin-embedded, and sliced for immunofluorescence staining. The experiment was repeated three times, with five mice each time.
[0101] Primary antibodies: OCN (1:100, Servicebio, GB11233), RUNX2 (1:200, Proteintech, 20700-1-AP).
[0102] Secondary antibodies: Alexa Fluor® 488-labeled goat anti-rabbit IgG (1:200, Servicebio, GB25303), Alexa Fluor® CY3-labeled goat anti-rabbit IgG (1:200, Servicebio, GB25303).
[0103] 2) Control group: Human osteochondrocyte stem cells stably transfected with empty plasmids were used to replace human osteochondrocyte stem cells overexpressing DSG2 gene, and other operations were the same as those of the experimental group.
[0104] The results of immunofluorescence staining of OCN and RUNX2 in bone organoids formed by subcutaneous transplantation in nude mice are shown in Fig.10 As shown, for Fig.10 The relative quantitative statistical results are as follows Fig.11 Compared with the empty vector transfection group ( Fig.10 Compared with the DSG2 gene-modified human osteochondrocyte stem cell group ( Fig.10There are more OCN and RUNX2 double-positive cells in the upper and lower figures of the second column from left to right in the figure; after human osteochondral stem cells were modified with DSG2 gene, the osteogenic differentiation ability of osteochondral stem cells was enhanced.
[0105] The sequences involved in the above embodiments are:
[0106] Amino acid sequence of DSG2 (SEQ ID No. 1)
[0107]
[0108] Coding region sequence of DSG2 (SEQ ID No. 2)
[0109]
[0110] Nucleotide sequence of DSG2
[0111]
[0112] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.
Claims
1. Recombinant osteochondral stem cells, characterized in that: The recombinant osteochondrocyte stem cells are prepared according to a method comprising the following steps: introducing a gene encoding desmoglein 2 into the isolated osteochondrocyte stem cells to obtain the recombinant osteochondrocyte stem cells; The desmoglein 2 is any of the following proteins: A1) a protein whose amino acid sequence is SEQ ID No. 1; A2) A fusion protein with the same function obtained by connecting a tag to the N-terminus and / or C-terminus of A1); The osteochondral stem cells are derived from humans.
2. The recombinant osteochondrogenic stem cell according to claim 1, characterized in that The recombinant osteochondrogenic stem cells express desmoglein 2.
3. A method for preparing recombinant osteochondrogenic stem cells, characterized in that: The method comprises the following steps: introducing a gene encoding desmoglein 2 into isolated osteochondrogenic stem cells to obtain the recombinant osteochondrogenic stem cells; The desmoglein 2 is any of the following proteins: A1) a protein whose amino acid sequence is SEQ ID No. 1; A2) A fusion protein with the same function obtained by connecting a tag to the N-terminus and / or C-terminus of A1); The osteochondral stem cells are derived from humans.
4. The method according to claim 3, characterized in that The recombinant osteochondrogenic stem cells express desmoglein 2.
5. A drug for promoting bone regeneration, characterized in that: The medicine consists of pharmaceutical excipients and the recombinant osteochondrogenic stem cells described in claim 1 or 2.
6. Use of recombinant osteochondral stem cells in the preparation of a drug for promoting bone regeneration, characterized in that: The recombinant osteochondral stem cells are the recombinant osteochondral stem cells according to claim 1 or 2.
7. Use of biomaterials in the preparation of drugs for promoting bone regeneration, characterized in that: The biological material is any of the following: B1), transgenic human osteochondral stem cells containing a nucleic acid molecule encoding desmoglein 2; B2), transgenic human osteochondral stem cells containing an expression cassette for desmoglein 2; The desmoglein 2 is any of the following proteins: A1) a protein whose amino acid sequence is SEQ ID No. 1; A2) A fusion protein having the same function as A1) is obtained by connecting a tag to the N-terminus and / or C-terminus of A1).
Citation Information
Patent Citations
Application of biological material related to desmogranulocyte glycoprotein 2 and medicine for inhibiting pathological hyperfunction of bone regeneration
CN117919451A
